Edwards Lifesciences Corp (EW) is going through an eventful period, marked by various institutional investments, class action lawsuits, earnings reports, and insider share transactions. Sabal Trust CO, JFG Wealth Management, and BankPlus Trust Department, among others, have adjusted their holdings in EW. Simultaneously, the company faces securities law violations lawsuits, urging investors to contact Levi & Korsinsky.
Scott Ullem, the CFO of Edwards Lifesciences, has also sold $796k in company stock. Despite these challenges, the company reported strong full-year growth in its Q4 2024 earnings call, and analysts anticipate more growth heading into 2025. Yet, the company has been downgraded at Wolfe, primarily due to concerns over its TAVR product. Nonetheless, some remain optimistic about Edwards Lifesciences' growth prospects. Despite the company being sued for securities fraud, the firm recently outlined its growth strategy during its Annual Investor Conference.
Edwards Lifesciences Corp EW News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 01 Mar 2025 10:20:43 GMT -
Rating -4
- Innovation 3
- Information 5
- Rumor -5
